Results for tag: "Tykerb"

Tykerb (lapatinib) is a targeted therapy drug used to treat certain types of advanced or metastatic non-small cell lung cancer (NSCLC). It is a kinase inhibitor, meaning it works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Tykerb is used in combination with chemotherapy to treat patients with NSCLC whose tumors have certain mutations in the epidermal growth factor receptor (EGFR) gene. Tykerb is also used to treat patients with HER2-positive breast cancer. The Tykerb market is a rapidly growing segment of the global oncology market. It is estimated that the Tykerb market will reach $1.2 billion by 2026, driven by the increasing prevalence of NSCLC and the growing demand for targeted therapies. The market is highly competitive, with several major players such as Novartis, Pfizer, and AstraZeneca. Additionally, there are several smaller companies such as Merck, GlaxoSmithKline, and Eli Lilly that are also competing in the market. Show Less Read more